INTRODUCTION AND OBJECTIVES: Surveillance guidelines for patients with non-muscle invasive bladder cancer (NMIBC) are variable and are largely based on expert opinion. The primary objective was to determine the feasibility. Secondary objectives were to test the hypotheses that patients randomized to low frequency (LF) surveillance experience improvement in patient-reported quality-of-life (QOL) and decreased procedure-related pain and cost compared to patients randomized to high frequency (HF) surveillance.
METHODS: Patients with low-or low-intermediate risk NMIBC were approached for study participation following a normal cystoscopy after 3 months from the incident tumor (clinicaltrials.gov identifier NCT02298998). Eligible patients were randomized 1:1 to HF vs. LF surveillance regimens. Patients in the HF group underwent cystoscopy every three months for 2 years, then every 6 months for 2 years, then annually following incident tumor removal. Patients in the LF group underwent cystoscopy at 9 months following the 3-month cystoscopy, then annually. QOL was assessed with the Functional Assessment of Bladder (FACT-BL) questionnaire.
RESULTS: Of total patients approached, 35 (61.4%) patients agreed to participate, 18 (31.6%) patients denied enrollment due to preference for HF surveillance and 4 (7%) patients enrolled but subsequently withdrew. 17 were randomized to the HF and 18 to LF group. Patients were well matched for baseline demographic variables and risk of recurrence. The median follow-up for the entire cohort was 18.5 months (interquartile range, 8.7-22.5). Over the course of the study, a total of 9 biopsies were performed post-randomization, including 3 (17.6%) in the LF and 6 (33.3%) in the HF groups (P [ 0.44). Out of those biopsies 2 (11.8%) and 4 (22.2%) were confirmed to be recurrences by pathology in the LF and HF groups, respectively (P [ 0.5). No patients progressed. Groups reported similar procedure-related discomfort and FACT-BL summary scores at study termination and similar changes from baseline. Estimated total out of pocket costs per patient for the HF group was $70.96 more compared to the LF group.
CONCLUSIONS: Randomization of patients to variable frequency surveillance cystoscopy is possible but challenging because many patients prefer a more frequent regimen. Differences in patientreported QOL and cost differences were minimal, calling into doubt the benefit of LF regimens. Further study is needed to determine if less frequent surveillance regimens are justified. Farmaceutici) is a novel water-soluble muco-adhesive conjugate of paclitaxel-hyaluronic acid (P-HA. Very favorable safety and efficacy after 6 weeks in BCG unresponsive CIS patients and after 6 weeks followed by 6þ6 months in Ta G1-G2 patients was previously reported. The excellent safety profile prompted the design of this trial to assess safety, tolerability and efficacy of P-HA administered for 12 consecutive weeks, followed by 12 monthly instillations, in BCG unresponsive/intolerant CIS patients.
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METHODS: This is an open-label, single arm, multicenter study to assess safety, tolerability and efficacy of P-HA administered in 20 patients with CIS, who are unresponsive or intolerant to BCG and unwilling or unfit for cystectomy. P-HA was administered weekly by intravesical instillation for 12 consecutive weeks (intensive phase), followed, in responsive patients, by 12 monthly instillations (maintenance). The primary endpoint is the overall safety profile. Secondary endpoints include i) efficacy after the intensive phase and after the entire treatment period, ii) compliance, iii) systemic absorption. The complete response (CR) is defined as a negative cystoscopy including biopsy of the urothelium and negative cytology. Patients who achieve a CR after intensive phase are followed up every 3 months for up to 1 year during maintenance, by flexible cystoscopy and urine cytology. For PK assessment, blood samples are collected after the 1stand 12th instillation. RESULTS: Of the 17 patients enrolled (15 M, 2 F), 11 have completed the 12 weeks intensive course. The instillations were very well tolerated; no patients withdrew from the study. Only one drug related AE (orticaryoid reaction) was reported in one patient after the 1st maintenance. All plasma samples collected at any time were below the limit of quantification (1 ng/mL). Of the 11 patients who completed the intensive course, 8 (73%) showed a CR. Of these, 1 was still disease free after 12 months, 1 relapsed after 3 months, 6 are continuing the monthly instillations without disease relapse.
CONCLUSIONS: Our preliminary data show that P-HA is very well tolerated when administered for up to 12 consecutive weeks, with no drug related AEs and no study withdrawal. 73% (8/11) of patients who completed the 12-week phase were disease free. No systemic absorption was observed at any time. The excellent tolerability for a prolonged treatment schedule coupled with the good clinical results support its further clinical development.
